By Adam Bonislawski
Fresh off a CHF 2.6 million ($2.85 million) Series A funding round, Swiss proteomics firm ProteoMedix is moving to validate blood-based protein biomarkers for diagnostic, prognostic, and companion diagnostic tests for prostate cancer.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.
The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.
The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.
An Australian study of personalized medicine has run into problems as it recruits patients.